Endo’s generics revenues slid during the first quarter but a sharp jump in sterile injectables sales helped the company to slash its net loss from a year earlier and beat analysts’ earnings forecasts.
Endo’s chief executive, Paul Campanelli, who is steering the firm’s turnaround, said he was not worried by the fall in non-injectable generics sales as he had expected 2019 “to be a year of transition” for the division, as it shifts to developing more complex drugs offering higher margins and facing fewer rivals
